For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...
Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
20hon MSN
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Bonnie Chapman said she began gaining weight after her mum's death and that her relationship with her famous dad soured after ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback